STEFANIA SORRENTINO

Dr. STEFANIA SORRENTINO

IRCCS Istituto Giannina Gaslini, Genoa, Liguria, Italy
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2011 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
Arnoldo PiccardoArnoldo Piccardo
Arnoldo Piccardo
Egesta LopciEgesta Lopci
Egesta Lopci
MCMassimo Conte
Massimo Conte
AGAlberto Garaventa
Alberto Garaventa
LFLuca Foppiani
Luca Foppiani
SFStefano Fanti
Stefano Fanti

20 September 2019 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
Arnoldo PiccardoArnoldo Piccardo
Arnoldo Piccardo
GMGiovanni Morana
Giovanni Morana
MPMatteo Puntoni
Matteo Puntoni
SCSara Campora
Sara Campora
SSSTEFANIA SORRENTINO
STEFANIA SORRENTINO
Egesta LopciEgesta Lopci
Egesta Lopci
To evaluate the diagnostic role of 18F-DOPA PET/CT at the time of staging, in children with Neuroblastoma (NB) and to investigate its ability to assess treatment response. We also investigated the prognostic value of 18F-DOPA PET/CT at the same time-points. Methods: We enrolled children with NB at onset. Before and after induction chemotherapy, all patients underwent 18F-DOPA PET/CT and 123I-mIBG scan plus SPECT/CT. 18F-DOPA PET/CT results were compared with those of 123I-mIBG WBS. For each modality, patient-based (PBA) and lesion-based analyses (LBA) were performed and sensitivity was calculated. We applied scoring systems to 123I-mIBG scan and 18F-DOPA PET/CT (i.e.123I-mIBG whole body score (WBS) and whole-body metabolic burden (WBMB), respectively) and evaluated the association between these parameters, the principal NB risk-factors and outcome. Results: We enrolled 16 high- and 2 intermediate-risk NB patients. On PBA, the sensitivity of 123I-mIBG WBS and 18F-DOPA PET/CT in detecting primary tumours, soft tissue and bone/bone-marrow metastases was 83%, 50% and 92%, versus 94%, 92% and 100%, respectively. On LBA, the sensitivity of 18F-DOPA PET/CT in detecting soft tissue and bone/bone-marrow metastases was 86% and 99% - significantly higher than that of 123I-mIBG WBS: 41% and 93%. After therapy, on PBA, the sensitivity of 123I-mIBG WBS and 18F-DOPA PET/CT in detecting primary tumours, soft tissue and bone/bone-marrow metastases was 72%, 33% and 38%, versus 83%, 75% and 54%, respectively. On LBA, the sensitivity of 18F-DOPA PET/CT in detecting soft tissue and bone/bone-marrow metastases was 77% and 86% - significantly higher than that of 123I-mIBG WBS (28% and 69%). During follow-up, 8 cases of disease progression and 5 deaths occurred. On multivariate analysis, only post-therapeutic 18F-DOPA WBMB (>7.5) was associated to progression-free survival. Conclusion: 18F-DOPA PET/CT is more sensitive than 123I-mIBG WBS in staging NB patients and evaluating disease persistence after chemotherapy. In a time-to-event analysis, post-therapeutic 18F-DOPA WBMB remained the only risk factor associated to disease progression.

1 June 2014 in Clinical Biochemistry
Verified
Journal Article
Closed access
SBSebastiano Barco
Sebastiano Barco
IGIulian Gennai
Iulian Gennai
GRGiorgio Reggiardo
Giorgio Reggiardo
BGBarbara Galleni
Barbara Galleni
LBLaura Barbagallo
Laura Barbagallo
GCGiuliana Cangemi
Giuliana Cangemi

22 February 2014 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
Arnoldo PiccardoArnoldo Piccardo
Arnoldo Piccardo
MPMatteo Puntoni
Matteo Puntoni
Egesta LopciEgesta Lopci
Egesta Lopci
MCMassimo Conte
Massimo Conte
LFLuca Foppiani
Luca Foppiani
AGAlberto Garaventa
Alberto Garaventa

12 March 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BBBruno De Bernardi
Bruno De Bernardi
LQlucia Quaglietta
lucia Quaglietta
RHRiccardo Haupt
Riccardo Haupt
ACAurora Castellano
Aurora Castellano
ETElisa Tirtei
Elisa Tirtei
AGAnna Rita Gigliotti
Anna Rita Gigliotti

1 December 2009 in European Journal of Cancer
Verified
Journal Article
Closed access
AGAnna Rita Gigliotti
Anna Rita Gigliotti
ACAndrea Di Cataldo
Andrea Di Cataldo
SSSTEFANIA SORRENTINO
STEFANIA SORRENTINO
SPStefano Parodi
Stefano Parodi
ARAntonino Rizzo
Antonino Rizzo
BBBruno De Bernardi
Bruno De Bernardi